Search clinical trials for: 0.05% cyclosporin eye drop

Total 18265 results

Peking University Third Hospital

Recruiting

The Effect of 0.05% CsA Eye Drops on Post-refractive Surgery Dry Eye

Dry Eye

China
Second Affiliated Hospital of Nanchang University

Completed

Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial

Vernal Keratoconjunctivitis | Cyclosporine 0.05% Eye Drops

China
Chengdu University of Traditional Chinese Medicine

Completed

AST Combined With 0.05% Cyclosporin Eye Drop Improve Corneal Nerve Density in Patients With SS Dry Eye (AST/SS)

Dry Eye | Sjogren's Syndrome | Ocular Surface Disease

China
Mahidol University

Unknown

0.05 Versus 0.1 mg Spinal Morphine for Reducing Morphine Requirement After Vaginal Hysterectomy

Pain | Vaginal Hysterectomy

Thailand
Centre Hospitalier Universitaire de Nice

Completed

Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma (PICABAS)

Carcinoma

France
Neal D. Bhatia, MD
LEO Pharma

Completed

Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.

Verruca Vulgaris | Common Warts

United States
Allergan

Completed

Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

Dry Eye Disease

United States
Formosa Pharmaceuticals, Inc.

Completed

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

Ocular Inflammation and Pain After Cataract Surgery

United States
Formosa Pharmaceuticals, Inc.

Completed

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery

Ocular Inflammation and Pain

United States, Puerto Rico
Formosa Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery

Ocular Inflammation and Pain After Cataract Surgery

United States
Peking University Third Hospital

Completed

Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment

Graft Versus Host Disease in Eye

China
Mahidol University

Completed

Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction

Meibomian Gland Dysfunction

Thailand
Seref istek
Usak State Hospital

Completed

The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye Syndrome

Dry Eye Syndrome
Dermavant Sciences GmbH

Completed

A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis

Atopic Dermatitis

Japan
LEO Pharma

Completed

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology

Actinic Keratosis

Germany
Universitaire Ziekenhuizen KU Leuven

Active, not recruiting

Beovu Experience UZ Leuven (BEL)

Age-Related Macular Degeneration

Belgium
Allergan

Completed

Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea

Conjunctivitis, Allergic

Korea, Republic of
Zhongshan Ophthalmic Center, Sun Yat-sen University

Recruiting

Microvascular and Inflammatory Responses of 0.05 Cyclosporine Eye Drop (II) in Treatment of Dry Eye

Dry Eye

China
Galderma R&D

Completed

A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam

Psoriasis

United States
Peplin

Completed

A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis

Actinic Keratosis

United States
Korea University
Samsung Medical Center; Asan Medical Center; Chonnam National University Hospital and other collaborators

Completed

Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis

Actinic Keratosis

Korea, Republic of
Arcutis Biotherapeutics, Inc.

Completed

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Creabilis SA

Completed

Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

United States, United Kingdom
LEO Pharma

Completed

A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities

Actinic Keratosis

Italy
Arcutis Biotherapeutics, Inc.

Completed

Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema

Atopic Dermatitis (Eczema)

United States
LEO Pharma

Completed

Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%

Actinic Keratosis

Australia, Germany
Ohio State University

Completed

The Response to Atropine Drops (RAD) Study

Myopia

United States
Peplin

Completed

PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities

Superficial Basal Cell Carcinoma

Australia
Massachusetts Eye and Ear Infirmary

Terminated

The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye

Dry Eye

United States
Galderma R&D

Completed

Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis

Psoriasis

United States
Vista Klinik

Not yet recruiting

Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to Aflibercept

Diabetic Macular Edema
Mahidol University

Completed

Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye

Stevens-Johnson Syndrome

Thailand
University of Siena

Recruiting

Clinical and Microbiological Comparison of 0.2% CHX and 0.05% CHX+0.05%CPC Mouthwashes in TPS Patients

Periodontitis | Gingivitis | Chlorhexidine | Cetylpyridinium Chloride

Italy
Arcutis Biotherapeutics, Inc.

Active, not recruiting

Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-OLE)

Atopic Dermatitis Eczema

United States, Canada
Actavis Inc.

Completed

A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis

Actinic Keratosis

United States
Bausch & Lomb Incorporated
Synteract, Inc.

Completed

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

Keratoconjunctivitis Sicca

United States
Farwaniya Hospital

Completed

Topical Cyclosporin A 0.05% Eye Drops for Management of Symptomatic Acquired Punctal Stenosis. A Prospective, Controlled Clinical Study.

Management of Punctal Stenosis

Kuwait
Bangabandhu Sheikh Mujib Medical University, Dhaka...

Completed

Effect of Solanum Melongena Extract in the Treatment of Arsenical Skin Lesion

Arsenical Keratosis

Bangladesh
Baylor College of Medicine
Allergan

Terminated

The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface (CsA)

Dry Eye

United States
G & W Laboratories Inc.

Completed

Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
University of Athens

Completed

Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion (INTRAMED-CRVO)

Retinal Vein Occlusion | Vascular Occlusive Disease
Innovative Medical

Completed

Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia

Pterygia

United States
Santen SAS

Completed

NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

Dry Eye

United States
Kaohsiung Medical University Chung-Ho Memorial...

Unknown

Bladder Irrigation 0.05% Lidocaine Decreases Postoperative CRBD

Bladder Discomfort

Taiwan
Taro Pharmaceuticals USA

Completed

Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study

Psoriasis

United States
Sun Pharmaceutical Industries Limited

Completed

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Keratoconjunctivitis Sicca | Dry Eye Disease

United States
Caroline Rickards

Completed

Pulsatile Perfusion Therapy Phase II (PPT2)

Hemorrhage

United States
Pavly Moawd

Completed

Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome

Dry Eye | Sjogren Syndrome

Egypt
Guerbet

Completed

Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis

Chronic Liver Disease | HepatoCellular Carcinoma

France
International Partnership for Microbicides, Inc.

Completed

A Phase I Pharmacokinetics and Safety Study of Two Dapivirine Intravaginal Gels

HIV Infections

Belgium

3

Subscribe